RxDoctor Payments Data

Jessica O'Neill, DO

Family Medicine · Garner, NCNPI 1437560547

Payments from drug & device makers

$2,157in general payments, 2019–2025

Across 109 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$437
  • Amgen$216
  • Abbott$193
  • Boehringer Ingelheim$154
  • AbbVie$146
  • AstraZeneca$137
  • plus $874 from 23 others

What the payments were for

  • Food & beverage$2,14299%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,157 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$64,155
Medicare patients
150
Services billed
1,437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$63,763
TrulicityDulaglutide44$45,633
EliquisApixaban37$40,769
RybelsusSemaglutide28$36,172
JardianceEmpagliflozin35$34,782
JanuviaSitagliptin Phosphate22$12,714
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$7,763
Tresiba Flextouch U-100Insulin Degludec11$5,195
Advair HfaFluticasone Propion/Salmeterol13$4,217
Atorvastatin Calcium418$3,958
Levothyroxine Sodium193$2,636
SynthroidLevothyroxine Sodium21$2,428
Bupropion XlBupropion Hcl87$1,893
Gabapentin88$1,619
Omeprazole180$1,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$437$99,93591 claims
Lilly USA, LLCTrulicity$73$45,63344 claims
PfizerEliquis$29$40,76937 claims
Boehringer IngelheimJardiance$154$34,78235 claims
MerckJanuvia$39$12,71422 claims
GSKAnoro Ellipta$11$7,76311 claims
AbbVieSynthroid$146$2,42821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Garner

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →